- The FDA has accepted Pfizer Inc's (NYSE: PFE) marketing application seeking approval for TicoVac under priority review status. TicoVac is the tick-borne encephalitis (TBE) vaccine for active immunization in individuals aged one and older.
- The anticipated action date is expected for August 2021.
- TBE is a viral infection of the brain and spine, transmitted to humans through the bite of an infected tick.
- The company's TBE vaccine is already marketed in Europe under the brand names TicoVac and FSME-Immun.
- Price Action: PFE is up 0.12% at $33.95 in premarket trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
